An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression — Suresh Durgam (2015) | RDL Network
An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression
Article 2015 en
Authors
SD
Suresh Durgam
WE
Willie Earley
AL
Alan Lipschitz
Abstract
1 min read
Cariprazine at 1.5 mg/day demonstrated consistent efficacy compared with placebo across outcomes and was generally well tolerated, suggesting efficacy for the treatment of bipolar I depression.
Discussion(0)
No comments yet. Be the first to comment.